This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Sarepta Therapeutics said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company’s U.S-approved gene therapy for a rare muscular…
Reuters Health Information